183 related articles for article (PubMed ID: 37928518)
1. Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation.
Zhu J; Wang Q; Ren H; Dong Y; Yin Y; Wang Q; Liang Z; Liu W; Wang Q; Wang B; Li Y
Front Immunol; 2023; 14():1274492. PubMed ID: 37928518
[TBL] [Abstract][Full Text] [Related]
2. [Effect and safety of 10-day decitabine-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation in 31 patients with acute myeloid leukemia/myelodysplastic syndrome].
Liu J; Cao YG; Zhang RL; Zhai WH; Chen X; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):472-478. PubMed ID: 37550202
[No Abstract] [Full Text] [Related]
3. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
[TBL] [Abstract][Full Text] [Related]
4. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
5. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D
Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582
[TBL] [Abstract][Full Text] [Related]
6. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome.
Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T
Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418
[TBL] [Abstract][Full Text] [Related]
8. [Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].
Zhao XL; Jiang EL; Zhai WH; Ma QL; Pang AM; Wei JL; He Y; Yang DL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):467-471. PubMed ID: 31340618
[No Abstract] [Full Text] [Related]
9. Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.
Tang X; Valdez BC; Ma Y; Zhang Q; Qu C; Dai H; Yin J; Li Z; Xu T; Xu Y; Chen J; Zhu X; Chen Z; Wu D; Andersson BS
Bone Marrow Transplant; 2021 Jul; 56(7):1674-1682. PubMed ID: 33637882
[TBL] [Abstract][Full Text] [Related]
10. Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
Ren Y; Liu F; Chen X; Zhang X; Zhao B; Wan Y; Lan Y; Li X; Yang W; Zhu X; Guo Y
Ann Hematol; 2024 Apr; 103(4):1345-1351. PubMed ID: 38316642
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells enhance the impact of KIR receptor-ligand mismatching on acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemia.
Zhang Y; Zheng H; Ren J; Luo X; Zheng Z; Zheng J; Zheng X; Chen Y; Chen Z; Hu J; Yang T
Hematol Oncol; 2021 Aug; 39(3):380-389. PubMed ID: 33848027
[TBL] [Abstract][Full Text] [Related]
13. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.
Cao YG; He Y; Zhang SD; Liu ZX; Zhai WH; Ma QL; Pang AM; Wei JL; Yang DL; Huang Y; Feng SZ; Jiang EL; Han MZ
Biol Blood Marrow Transplant; 2020 Feb; 26(2):285-291. PubMed ID: 31494229
[TBL] [Abstract][Full Text] [Related]
14. Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease.
Wang QY; Li Y; Liang ZY; Yin Y; Liu W; Wang Q; Dong YJ; Sun YH; Xu WL; Ren HY
Cancer Manag Res; 2019; 11():10195-10203. PubMed ID: 31824191
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Observation of Treatment Outcomes Using Decitabine-Combined Standard Conditioning Regimens Before Transplantation in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
Li Y; Cheng L; Xu C; Chen J; Hu J; Liu N; Lan S; Xie J; Sun T; Wang L; Zhang Y; Sun Y; Chen S; Hu L
Front Oncol; 2021; 11():702239. PubMed ID: 34504785
[TBL] [Abstract][Full Text] [Related]
16. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
Sommer S; Cruijsen M; Claus R; Bertz H; Wäsch R; Marks R; Zeiser R; Bogatyreva L; Blijlevens NMA; May A; Duyster J; Huls G; van der Velden WJFM; Finke J; Lübbert M
Leuk Res; 2018 Sep; 72():20-26. PubMed ID: 30064039
[TBL] [Abstract][Full Text] [Related]
17. Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML.
Cao XY; Chen JQ; Wang H; Ma W; Liu WW; Zhang FF; Xue S; Dong L; Liu T; Zhao XZ; Liu CC; Xu X; He Y; Wang L; Wang JL
Ann Med; 2023 Dec; 55(1):388-400. PubMed ID: 36629738
[TBL] [Abstract][Full Text] [Related]
18. [Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome].
Zheng H; Wang J; Zhou J; Wang P; Fu C; Wu D; Sun A; Qiu H; Jin Z; Han Y; Tang X; Ma X
Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):121-4. PubMed ID: 25778887
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
